SCHEMBL6523487

SCHEMBL6523487

COc1ccc(NC(=O)Nc2ccccc2CN2C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1OC

nearest known ligand 0.53

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
AR P10275 5/20 0.51
PGR P06401 1/20 0.51
HDAC1 Q13547 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3528494 0.90 AR (0.52) ARPGRHDAC1
SCHEMBL6527746 0.90 AR (0.56) ARPGRHDAC1
SCHEMBL6523411 0.89 AR (0.53) ARPGRHDAC1
SCHEMBL6521553 0.89 AR (0.54) ARPGRHDAC1
SCHEMBL1970543 0.88 AR (0.56) ARPGRHDAC1
SCHEMBL6527722 0.88 AR (0.51) ARPGRHDAC1
SCHEMBL1974727 0.88 AR (0.55) ARPGRHDAC1
SCHEMBL6521027 0.88 AR (0.53) ARPGRHDAC1
SCHEMBL6525853 0.87 AR (0.53) ARPGRHDAC1
SCHEMBL6525850 0.87 AR (0.52) ARPGRHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110053947-A1 Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof SANOFI-AVENTIS (FR) 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053947-A1 Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof PGC, LIPC, CEL AR 1971/4885PGR 1141/4885HDAC1 1295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.